drugset / Trial / NCT01263470
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study was to evaluate the dose-response relationships of alogliptin, once daily (QD) to an α-glucosidase inhibitor, three times daily (TID), to determine the optimal clinical dose for type 2 diabetic patients.
Timeline
- Start
- 2007-01
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alogliptin | Unknown | 6.25 mg | Oral |
| Subject | Alogliptin | Unknown | 12.5 mg | Oral |
| Subject | Alogliptin | Unknown | 25 mg | Oral |
| Subject | Alogliptin | Unknown | 50 mg | Oral |
| Comparator | Voglibose | Small molecule | 0.2 mg | Oral |